The growth factor midkine antagonizes VEGF signaling in vitro and in vivo

Neoplasia

Volumn 10, Issue 4, 2008, Pages 340-346

  Van Der Horst, Edward Htun ^a,b   Frank, Brendon T ^a   Chinn, Lawrence ^a,b   Coxon, Angela ^a   Li, Shyun ^a   Polesso, Fanny ^a   Slavin, Anthony ^a   Ruefli Brasse, Astrid ^a   Wesche, Holger ^a  

^a AMGEN INC   (United States)

^b OncoMed Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; METALLOPROTEINASE 2; MIDKINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 41649101046     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07820     Document Type: Article

References (22)

1. Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25, 581-611.
2. Ferrara N and Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature 438, 967-974.
3. Shibuya M and Claesson-Welsh L (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312, 549-560.
4. Folkman J (2003). Angiogenesis and apoptosis. Semin Cancer Biol 13, 159-167.
5. Dvorak HF (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20, 4368-4380.
6. 1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 117, 5405-5415.
7. Kadomatsu K and Muramatsu T (2004). Midkine and pleiotrophin in neural development and cancer. Cancer Lett 204, 127-143.
8. Herradon G, Ezquerra L, Nguyen T, Silos-Santiago I, and Deuel TF (2005). Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/ midkine developmental gene family. Biochem Biophys Res Commun 333, 714-721.
9. Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, Okamoto K, Oda M, Sakuma S, Aikou T, et al. (2000). Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 83, 701-706.
10. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, and Ochiai T (2003). Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 94, 628-632.
11. Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F, et al. (2007). Midkine as a novel target for antibody therapy in osteosarcoma. Biochem Biophys Res Commun 358, 757-762.
12. Ruan M, Ji T, Wu Z, Zhou J, and Zhang C (2007). Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 36, 159-164.
13. Muramaki M, Miyake H, Hara I, and Kamidono S (2003). Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. Clin Cancer Res 9, 5152-5160.
14. Choudhuri R, Zhang HT, Donnini S, Ziche M, and Bicknell R (1997). An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57, 1814-1819.
15. van der Horst EH, Weber I, and Ullrich A (2005). Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3- stimulated signaling pathway in glioma. Int J Cancer 113, 689-698.
16. Storgard C, Mikolon D, and Stupack DG (2005). Angiogenesis assays in the chick CAM. Methods Mol Biol 294, 123-136.
17. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, et al. (2005). Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7, 251-261.
18. Coxon A, Bolon B, Estrada J, Kaufman S, Scully S, Rattan A, Duryea D, Hu YL, Rex K, Pacheco E, et al. (2002). Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum 46, 2604-2612.
19. 1-integrin activation. Mol Cell Biol 22, 2830-2841.
20. Muramatsu T (2002). Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo) 132, 359-371.
21. Ferrara N (2004). Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl 1), 2-10.
22. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, and Stetler-Stevenson WG (2003). TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114, 171-180.